Business
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “As we mark one year since our transformation from Sosei Heptares to Nxera Pharma, I am incredibly proud of the progress we’ve made and how we have evolved. Our new identity has unified the
About this update from Nxera Pharma Co., Ltd.
[{"type":"image","alt":"Nxera Pharma","displaySize":"","headline":null,"caption":"Nxera Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MMtO8FGLy1ULu25TBGkF3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638","width":300,"height":101}},"lazy":false},{"type":"text","content":"Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found here.","length":255,"tagName":"p"},{"type":"text","content":"Chris Cargill, President and CEO of Nxera, commented: “As we mark one year since our transformation from Sosei Heptares to Nxera Pharma, I am incredibly proud of the progress we’ve made and how we have evolved. Our new identity has unified the Group and helped clarify our mission while clearly signalling our intent to lead the next era of biopharmaceutical innovation in Japan and globally. The strides we’ve made over the past year is a testament to the strength of our people, our partnerships, and the power of our NxWave™ platform to deliver promising new candidates for development across major disease areas with great unmet need.","length":638,"tagName":"p"},{"type":"text","content":"“We expect 2025 to be an important year across both for our partnered and in-house portfolios. With key data readouts anticipated from multiple clinical trials and several new studies due to commence, we are well positioned to deliver significant value for patients and shareholders alike.”","length":290,"tagName":"p"},{"type":"text","content":"Operational Highlights for Q1 2025","length":34,"tagName":"p"},{"type":"text","content":"Development and commercialization agreements","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Assignment of Japan and Asia-Pacific (ex-China) rights for cenerimod, a promising S1P1 receptor modulator for autoimmune diseases, to Viatris","length":141,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Receipt of upfront payment of US$10 million, with addi...